Difference between revisions of "Talquetamab (Talvey)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/talquetamab NCI Drug Dictionary]: A bispecific humanized monoclonal antibody...") |
Warner-admin (talk | contribs) m (Text replacement - " (NCT[0-9]{8})" to " https://clinicaltrials.gov/ct2/show/$1") |
||
| Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Multiple myeloma]]=== | ===[[Multiple myeloma]]=== | ||
| − | #'''MonumenTAL-1:''' Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Askari E, Mateos MV, Costa LJ, Caers J, Verona R, Girgis S, Yang S, Goldsmith RB, Yao X, Pillarisetti K, Hilder BW, Russell J, Goldberg JD, Krishnan A. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022 Dec 15;387(24):2232-2244. Epub 2022 Dec 10. [https://doi.org/10.1056/nejmoa2204591 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36507686/ PubMed] NCT03399799 | + | #'''MonumenTAL-1:''' Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Askari E, Mateos MV, Costa LJ, Caers J, Verona R, Girgis S, Yang S, Goldsmith RB, Yao X, Pillarisetti K, Hilder BW, Russell J, Goldberg JD, Krishnan A. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022 Dec 15;387(24):2232-2244. Epub 2022 Dec 10. [https://doi.org/10.1056/nejmoa2204591 link to original article] [https://pubmed.ncbi.nlm.nih.gov/36507686/ PubMed] https://clinicaltrials.gov/ct2/show/NCT03399799 |
==Also known as== | ==Also known as== | ||
Revision as of 12:51, 6 June 2023
Mechanism of action
From the NCI Drug Dictionary: A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells.
Preliminary data
Multiple myeloma
- MonumenTAL-1: Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Askari E, Mateos MV, Costa LJ, Caers J, Verona R, Girgis S, Yang S, Goldsmith RB, Yao X, Pillarisetti K, Hilder BW, Russell J, Goldberg JD, Krishnan A. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022 Dec 15;387(24):2232-2244. Epub 2022 Dec 10. link to original article PubMed https://clinicaltrials.gov/ct2/show/NCT03399799
Also known as
- Code names: JNJ-64407564